LATS2 and breast cancer: In other cancer types, LATS1 and LATS2 expression can be decreased by the hypermethylation of their promoter, as reported in breast cancer, soft tissue sarcoma, gastric cancer, non-small cell lung carcinoma, clear cell carcinomas of the kidney, and nasopharyngeal, and oral cavity squamous cell carcinomas, or by loss of heterozygosity, as observed in ovarian, cervical, breast, and liver cancers [11,44,45,46,47].